Athersys

Athersys FCF Conversion

Delisted·Oct 1, 2026

The FCF Conversion Rate (FCF/EBITDA) of Athersys (ATHXQ) as of Nov 20, 2026 is 81.82 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 89.18 % — a change of -8.25% (lower).

FCF Conversion

81.82 %

YoY

-8.25%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Athersys is 2022 81.82 % . FCF Conversion Rate (FCF/EBITDA) of Athersys was 2021 89.18 % . It decreases by -8.25% lower compared to the previous year.

The Athersys FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2015
84.59 USD
Jan 1, 2016
82.40 USD
Jan 1, 2017
75.40 USD
Jan 1, 2018
61.29 USD
Jan 1, 2019
80.54 USD
Jan 1, 2020
79.95 USD
Jan 1, 2021
89.18 USD
Jan 1, 2022
81.82 USD
The Athersys FCF Conversion history
YEARFCF ConversionYoY
81.82 %-8.25%
89.18 %+11.54%
79.95 %-0.73%
80.54 %+31.41%
61.29 %-18.72%
75.40 %-8.49%
82.40 %-2.59%
84.59 %-28.41%
118.16 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Athersys Stock analysis

What does Athersys do? Athersys, Inc. generates revenue through the development and commercialization of its MultiStem (invimestrocel) cell therapy, an allogeneic stem cell product candidate derived from adult bone marrow. The company focuses on late-stage clinical development for critical care, neurological conditions, inflammatory disorders, pulmonary conditions, and cardiovascular disease. Its lead product, MultiStem, is currently in Phase III clinical trials for ischemic stroke under the MASTERS-2 study. Athersys targets medical institutions and healthcare providers seeking innovative treatments for unmet medical needs in multiple disease areas. The company's primary product, MultiStem, is manufactured from human stem cells obtained from adult bone marrow and alternative tissue sources. It is designed to address conditions including critical care indications, neurological disorders, inflammatory and immune disorders, pulmonary conditions, and cardiovascular disease. Athersys conducts Phase III trials for ischemic stroke treatment, aiming to secure regulatory approval for broader market access. Revenue streams are expected to emerge post-approval through therapeutic product sales to hospitals and clinics. Athersys, Inc. operates in the biotechnology sector with a focus on regenerative medicine, leveraging its MultiStem platform to address unmet medical needs. The company's clinical development strategy centers on late-stage trials for ischemic stroke and other conditions, targeting healthcare providers and medical institutions as key customers. Commercialization of MultiStem will likely involve partnerships with healthcare systems for treatment protocols and patient access. Athersys is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Athersys stock

FCF Conversion Rate (FCF/EBITDA) of Athersys is 81.82 % in 2022.

FCF Conversion Rate (FCF/EBITDA) of Athersys changed from 89.18 % to 81.82 %, representing a -8.25% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Athersys since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Athersys with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Athersys

All Key Metrics — Athersys